Mirae Asset Global Investments Co., Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $24 Billion
- Q4 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,090 shares of CRNX stock, worth $105,863. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,090
Previous 2,895
6.74%
Holding current value
$105,863
Previous $147,000
6.8%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$311 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$238 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$213 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$210 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$186 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.84B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...